KNSA — Kiniksa Pharmaceuticals International Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousMid CapHigh Flyer

Market Cap
$3.15bn
Enterprise Value
$2.80bn
Revenue
$423.24m

Annual balance sheet for Kiniksa Pharmaceuticals International, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	323	182	191	206	244
Net Total Accounts Receivable
Net Total Receivables	—	3.98	20.3	21.3	41.7
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	333	196	243	276	332
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	10.6	8.38	7.04	12.7	11
Net Intangible Assets
Other Long Term Assets
Total Assets	349	233	460	526	581
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Total Other Current Liabilities
Total Current Liabilities	31.8	44.8	47.1	63.7	101
Total Long Term Debt
Total Debt
Total Other Liabilities
Total Liabilities	37.5	47.8	63.5	87.5	142
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	312	185	396	439	438
Total Liabilities & Shareholders' Equity	349	233	460	526	581
Total Common Shares Outstanding